SOURCE: Goldman Small Cap Research, Inc.

November 13, 2013 09:30 ET

Nuvilex: The Triple Threat

BALTIMORE, MD--(Marketwired - Nov 13, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that with a presence in disparate but potentially related markets, Nuvilex, Inc. (OTCQB: NVLX) is a triple threat that offers investors huge potential. With home run potential in three large segments, Nuvilex offers investors a unique opportunity to invest in an emerging biotech that has a presence in arguably the three most important and high profile sectors of the health care arena. Therefore, for investors seeking to minimize risk by identifying a company with multiple shots on goal, Nuvilex clearly fits the bill.

Target #1: Cancer -- a multi-billion dollar market
Earlier this year, Nuvilex acquired exclusive worldwide rights to a novel, live-cell encapsulation-based platform technology for any and all cancer types, including a pancreatic cancer treatment that successfully completed Phase 2 clinical trials. In those trials, this platform, which essentially serves as an existing therapy booster, has been shown to be very effective while resulting in reduced drug toxicity and enhanced patients' quality of life. 

Separately, the platform has demonstrated a strong indication for the treatment of breast cancer. It is possible that the results with breast cancer could ultimately show that the cell encapsulation technology can also be substantially positive, and perhaps even more so, for this indication than they are for pancreatic cancer.

Target #2: Diabetes -- $100B+ market
Nuvilex has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pte. Ltd. This new treatment category represents an even larger opportunity for the company than its current cancer treatment initiatives.

In a proof of principle animal study, the encapsulated cells appear to have acted as an artificial or replacement pancreas which has tremendous value in treatment of diabetes. Armed with these valuable study results, management will likely take steps that will ultimately lead to the initiation of human clinical trials which, in turn, will serve to substantially raise the company's value and its profile.

Target #3: Medical Marijuana -- multi-billion dollar market
With exclusive worldwide rights in the entire oncology space, and with the ability to produce the appropriate live cells for encapsulation, management may elect to study the effects of multiple cannabinoid (active constituents of Cannabis)-based cancer treatments via its subsidiary, Medical Marijuana Sciences, Inc. Nuvilex's combination CBD-based cancer studies with live-cell encapsulation therapy development might result in bringing a highly effective product and new delivery system for use to treat the most serious and deadly forms of cancer, which would be place Nuvilex near the head of the medical marijuana product development class. 

This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit: www.nuvilex.com.

Contact Information